Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1997-9-9
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Aspartate Carbamoyltransferase, http://linkedlifedata.com/resource/pubmed/chemical/Aspartic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Dipyridamole, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Interferons, http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/NSC 224131, http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Nucleotides, http://linkedlifedata.com/resource/pubmed/chemical/Phosphonoacetic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase
pubmed:status
MEDLINE
pubmed:issn
1060-0051
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
206-10
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:9229317-Adenocarcinoma, pubmed-meshheading:9229317-Antimetabolites, Antineoplastic, pubmed-meshheading:9229317-Aspartate Carbamoyltransferase, pubmed-meshheading:9229317-Aspartic Acid, pubmed-meshheading:9229317-Clinical Trials, Phase II as Topic, pubmed-meshheading:9229317-Colorectal Neoplasms, pubmed-meshheading:9229317-Combined Modality Therapy, pubmed-meshheading:9229317-Dipyridamole, pubmed-meshheading:9229317-Drug Administration Schedule, pubmed-meshheading:9229317-Drug Synergism, pubmed-meshheading:9229317-Enzyme Inhibitors, pubmed-meshheading:9229317-Female, pubmed-meshheading:9229317-Fluorouracil, pubmed-meshheading:9229317-Humans, pubmed-meshheading:9229317-Immunologic Factors, pubmed-meshheading:9229317-Infusions, Intravenous, pubmed-meshheading:9229317-Injections, Intravenous, pubmed-meshheading:9229317-Interferons, pubmed-meshheading:9229317-Leucovorin, pubmed-meshheading:9229317-Liver Neoplasms, pubmed-meshheading:9229317-Male, pubmed-meshheading:9229317-Methotrexate, pubmed-meshheading:9229317-Middle Aged, pubmed-meshheading:9229317-Multicenter Studies as Topic, pubmed-meshheading:9229317-Neoplasm Proteins, pubmed-meshheading:9229317-Nucleotides, pubmed-meshheading:9229317-Palliative Care, pubmed-meshheading:9229317-Phosphonoacetic Acid, pubmed-meshheading:9229317-Randomized Controlled Trials as Topic, pubmed-meshheading:9229317-Thymidylate Synthase
pubmed:year
1996
pubmed:articleTitle
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
pubmed:affiliation
Virchow-Kjinikum Humboldt-University, Berlin Robert-Rössle-Klinik, Germany. koehne@rrk-berlin.de
pubmed:publicationType
Journal Article, Comparative Study, Review